Skip to main content
Journal cover image

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.

Publication ,  Journal Article
Gheorghiade, M; Gattis, WA; Barbagelata, A; Adams, KF; Elkayam, U; Orlandi, C; O'Connor, CM ...
Published in: Am Heart J
February 2003

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

February 2003

Volume

145

Issue

2 Suppl

Start / End Page

S51 / S54

Location

United States

Related Subject Headings

  • Tolvaptan
  • Research Design
  • Receptors, Vasopressin
  • Prospective Studies
  • Patient Selection
  • Humans
  • Hospitalization
  • Heart Failure
  • Double-Blind Method
  • Disease Progression
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gheorghiade, M., Gattis, W. A., Barbagelata, A., Adams, K. F., Elkayam, U., Orlandi, C., … Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators, . (2003). Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J, 145(2 Suppl), S51–S54. https://doi.org/10.1067/mhj.2003.154
Gheorghiade, Mihai, Wendy A. Gattis, Alejandro Barbagelata, Kirkwood F. Adams, Uri Elkayam, Cesare Orlandi, Christopher M. O’Connor, and Christopher M. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators. “Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.Am Heart J 145, no. 2 Suppl (February 2003): S51–54. https://doi.org/10.1067/mhj.2003.154.
Gheorghiade M, Gattis WA, Barbagelata A, Adams KF, Elkayam U, Orlandi C, O’Connor CM, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J. 2003 Feb;145(2 Suppl):S51–S54.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

February 2003

Volume

145

Issue

2 Suppl

Start / End Page

S51 / S54

Location

United States

Related Subject Headings

  • Tolvaptan
  • Research Design
  • Receptors, Vasopressin
  • Prospective Studies
  • Patient Selection
  • Humans
  • Hospitalization
  • Heart Failure
  • Double-Blind Method
  • Disease Progression